167 related articles for article (PubMed ID: 38423596)
1. PRIM2: A Marker of MYC-driven Hyper-proliferation, Disease Progression, Tumor Aggressiveness and Poor Survival in Glioma Patients.
Sun R; Shao X; Akter F; Zahid KR; Yao S; Ma L; Xu G
Cancer Genomics Proteomics; 2024; 21(2):186-202. PubMed ID: 38423596
[TBL] [Abstract][Full Text] [Related]
2. miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.
Wang H; Yan X; Ji LY; Ji XT; Wang P; Guo SW; Li SZ
Technol Cancer Res Treat; 2017 Aug; 16(4):497-511. PubMed ID: 26868851
[TBL] [Abstract][Full Text] [Related]
3. PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer.
Wang T; Tang T; Jiang Y; He T; Qi L; Chang H; Qiao Y; Sun M; Shan C; Zhu X; Liu J; Wang J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884433
[TBL] [Abstract][Full Text] [Related]
4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
Tian QS; Zhang Q; Huang W
Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
[TBL] [Abstract][Full Text] [Related]
5. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
6. Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Menezes WP; Silva VAO; Gomes INF; Rosa MN; Spina MLC; Carloni AC; Alves ALV; Melendez M; Almeida GC; Silva LSD; Clara C; da Cunha IW; Hajj GNM; Jones C; Bidinotto LT; Reis RM
Cells; 2020 Feb; 9(2):. PubMed ID: 32093414
[TBL] [Abstract][Full Text] [Related]
7. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
8. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma.
Gui S; Chen P; Liu Y; Chen Q; Cheng T; Lv S; Zhou T; Song Z; Xiao J; He W; Yuan S; Cheng Z
Biochem Biophys Res Commun; 2021 Nov; 577():130-138. PubMed ID: 34517210
[TBL] [Abstract][Full Text] [Related]
9. Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.
Kao Y; Tsai WC; Chen SH; Hsu SY; Huang LC; Chang CJ; Huang SM; Hueng DY
Sci Rep; 2021 Sep; 11(1):18541. PubMed ID: 34535705
[TBL] [Abstract][Full Text] [Related]
10.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
11.
Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
Front Immunol; 2022; 13():974346. PubMed ID: 36275718
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of SOX9 indicates a better prognosis and inhibits the growth of glioma cells by inducing cell cycle arrest.
Gao J; Zhang JY; Li YH; Ren F
Int J Clin Exp Pathol; 2015; 8(9):10130-8. PubMed ID: 26617720
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
Zhang X; Sun X; Guo C; Li J; Liang G
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
[TBL] [Abstract][Full Text] [Related]
14. Systems biology based meth-miRNA-mRNA regulatory network identifies metabolic imbalance and hyperactive cell cycle signaling involved in hepatocellular carcinoma onset and progression.
Zahid KR; Su M; Khan ARR; Han S; Deming G; Raza U
Cancer Cell Int; 2019; 19():89. PubMed ID: 31007607
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.
Vastrad B; Vastrad C; Godavarthi A; Chandrashekar R
Med Oncol; 2017 Sep; 34(11):182. PubMed ID: 28952134
[TBL] [Abstract][Full Text] [Related]
16. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
17. Prognostic power of a lipid metabolism gene panel for diffuse gliomas.
Wu F; Zhao Z; Chai RC; Liu YQ; Li GZ; Jiang HY; Jiang T
J Cell Mol Med; 2019 Nov; 23(11):7741-7748. PubMed ID: 31475440
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
19. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
20. Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas.
Xu R; Han M; Xu Y; Zhang X; Zhang C; Zhang D; Ji J; Wei Y; Wang S; Huang B; Chen A; Zhang Q; Li W; Sun T; Wang F; Li X; Wang J
J Transl Med; 2017 Jul; 15(1):165. PubMed ID: 28754121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
